We're all set for a new experience. To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open11,670
High11,875
Low11,540
Prev. Close11,819
Avg. Traded Price11,745.73
Volume24,263

MARKET DEPTH

info2
Total bid0.00
Total ask1.00
OrdersQtyBid
000
000
000
000
000
AskQtyOrders
1181911
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

11,540.0011 hours ago
11,875.007 hours ago
arrow

LOWER/UPPER CIRCUITS

9,340.00
14,008.00
arrow
Neuland Laboratories Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteInterest Coverage Ratio,is 41.43, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
noteDebt to Equity Ratio,of 0.09 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
noteStock Price,rose 93.2% and outperformed its sector by 69.61% in the past year.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 56.34%
Net profit growth 5Y CAGR : 78.75%
Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The company provides solutions across the full range of the pharmaceutical industry’s chemistry requirements from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life-cycle as well as commercial launch. Its core competency lies in the application of strong process chemistry to manufacturing in a regulatory compliant environment. Neuland has been at the forefront of facilitating and accelerating drug development and cGMP manufacturing of APIs.
personal

Grow your wealth with more research recommendations

+91